The first direct study identifying the central role of the 5-HT2A receptor for the action of psychedelics in humans emerged from a clinical study by Vollenweider et al. (1998), which showed that psilocybin effects were inhibited by 5-HT2A receptor-selective antagonist ketanserin or atypical antipsychotic risperidone but were developed by dopamine antagonist and common antipsychotic haloperidol.

These data provided

The first evidence that the effects of psilocybin in humans were due to activation of the 5-HT2A receptor. Later, Vollenweider and good movies to watch on shrooms conducted additional clinical studies, discussed later, of various aspects of psilocybin action and showed that ketanserin could prevent many of those effects.

Kometer et al. (2012) conducted a randomized, double-blind study in 17 healthy human subjects. At 4 different days, subjects received placebo, psilocybin (215 μg / kg), 5-HT2A antagonist ketanserin (50 mg, p.o.), or psilocybin and ketanserin.

Emotional conditions were assessed, and possible behavioral and event estimates were used to measure facial recognition and targeted behavioral behaviors with respect to emotional symptoms. Psilocybin was found to improve positive mood and reduce thegaiavoice.com of bad facial expressions.

  • In addition, psilocybin increased goal-oriented
  • Behaviors compared to negative indicators
  • Facilitated positive outcomes but
  • Prevented negative consecutive negative
  • Emotions, and valence reduced
  • The P300 factor by dependence

Ketanserin given alone did

Not cause side effects but inhibited the development of psilocybin-induced sensitivity and reduced visual acuity. This study showed that psilocybin alters mood bias in all different brain domains and that activation of 5-HT2A receptors is central to emotional control and emotional facial recognition in healthy subjects.

The authors suggest that their findings contribute not only to the pathophysiology of ineffective The Gaia Voice discrimination, but may also provide a framework for clarifying the mechanisms underlying the effects of psilocybin's putative antidepressant.

Quednow et al. (2012) investigated

The role of 5-HT2A receptors in the automatic (sensorimotor gating) and control mechanisms (Stroop interference) administered in the form of moderate psychosis using psilocybin (260 μg / kg) in 16 healthy individuals. premature or with 5-HT2A- selective receptor mushroom ketanserin (40 mg) or placebo, using.

  • Placebo-controlled, crossover
  • Counterbalanced, and
  • Double-blind design

They found that the loss

Caused by psilocybin to automatic and controlled inhibition was significantly reduced by ketanserin. They reiterated their previous findings that many hallucinogenic effects of psilocybin were eliminated by ketanserin.

Kometer et al. (2013) examined the effects of psilocybin (215 μg / kg) on โ€‹โ€‹both α oscillations that regulate cortical excitement and premature visual stimulation of P1 and N170 in 16 healthy human subjects. They used double-blind, placebo-controlled, within the title, random design.

Psilocybin usually significantly increased the 5D-ASC score after previous placebo treatment, but not after good movies to watch on shrooms treatment. Psilocybin significantly decreased both prestimulus parieto-occipatal α and decreased N170 potency associated with the appearance of vision changes, including hallucinations.

Pre-administration of the 5-HT2A antagonist ketanserin (50 mg) blocked all of these effects. The authors conclude that 5-HT2A receptor activation by psilocybin radically alters neurophysiological and phenomenological visual indices. They also suggest that activation of the 5-HT2A receptor may trigger processing mode when cortical excitement is stimulated